{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:27:30Z","timestamp":1790566050160,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The understanding of usefulness of immunoglobulin replacement therapy (IgRT) for hypogammaglobulinemia (HGG) in patients with hematologic malignancies (HM) has changed over time. This is mainly caused by the introduction of new treatment, such as B\u2010cell targeted agents. We investigated the real world effectiveness of IgRT on the severe bacterial infection (SBI) incidence in patients with HGG secondary to HMs using a Japanese claims database provided by MDV Inc.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients who were diagnosed with both HM and HGG from May 2010 to March 2021 in this database and prescribed IgRT with the dosage of &gt; 5\u00a0g\/month were eligible. We compared the SBI incidence, which was defined as a prescription of intravenous antibacterial agents during hospitalization, between during 12\u2010month before IgRT initiation (baseline period) and 12\u2010month after IgRT initiation (follow\u2010up period).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total 1621 eligible patients, 37.9% and 17.7% of patients were for non\u2010Hodgkin's lymphoma (NHL) and multiple myeloma (MM), respectively. A total of 24.4% of patients were hematopoietic stem cell transplantation (HSCT) recipients. In the follow\u2010up period, SBI incidence significantly decreased than that in the baseline period (2.3 events per person\u2010year vs. 0.9; <jats:italic>p<\/jats:italic> &lt; 0.001). Similar results were observed in various subgroups such as patients who were diagnosed with NHL or MM, treated with anti\u2010CD20 monoclonal antibody or anti\u2010CD38 monoclonal antibody, or HSCT recipients. In the small number of patients whose baseline serum IgG levels were available (<jats:italic>n<\/jats:italic> = 28), decrease of the SBI incidence in the follow\u2010up period was observed regardless of IgG levels. A reduction of the SBI incidence was seen in patients with &lt; 400\u00a0mg\/dL (2.6\u00a0vs. 0.6).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IgRT may decrease the SBI incidence in patients with HGG secondary to HM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration:<\/jats:title><jats:p>Registered at UMIN Clinical Trials Registry, UMIN000047418<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70091","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T10:37:13Z","timestamp":1751452633000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study"],"prefix":"10.1002","volume":"6","author":[{"given":"Keichiro","family":"Mihara","sequence":"first","affiliation":[{"name":"International Center for Cell and Gene Therapy Fujita Health University Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakazu","family":"Kawase","sequence":"additional","affiliation":[{"name":"International Center for Cell and Gene Therapy Fujita Health University Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Miyama","sequence":"additional","affiliation":[{"name":"International Center for Cell and Gene Therapy Fujita Health University Toyoake Aichi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Medilead Inc. Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1077-6393","authenticated-orcid":false,"given":"Ayako","family":"Shoji","sequence":"additional","affiliation":[{"name":"Medilead Inc. Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Matsumaru","sequence":"additional","affiliation":[{"name":"CSL Behring K.K. Minato\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001596\u2010z"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13264"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.11.011"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00033"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.126763"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211035272"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000717"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020004079"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.28"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198810063191403"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102257.1995.tb00322.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(94)90180\u20105"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2017.11.014"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199009133231103"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010139\u20101\u2010200307010\u201000007"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0031"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0002"},{"key":"e_1_2_12_20_1","volume-title":"Management of Immunotherapy\u2010Related Toxicities, Version 1, 2024","author":"Thompson J. A.","year":"2023"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.06.019"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.101261"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201023\u20100049"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19203"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801\u2010022\u201000296\u20105"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025298"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992761"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003189.pub4"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(19)30506\u20106"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.12.026"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011231"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:49:38Z","timestamp":1756288178000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1002\/jha2.70091"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70091","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2025-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70091"}}